Inhibikase Therapeutics, Inc. (IKT) stock
IKTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.38−0.07 (-4.83%)
Close on Nov 17, 2026Market cap $192.56MP/E –Yield –
Inhibikase Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Inhibikase Therapeutics's operating margin for the twelve months ending Sep 30, 2024 was -2006393700.0%. For fiscal 2023 it was -7712.0%, against -14686.2% the year before.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | -7712.0% | +6974.2 |
| FY2022 | Dec 31, 2022 | -14686.2% | −14209.9 |
| FY2021 | Dec 31, 2021 | -476.2% | −72.7 |
| FY2020 | Dec 31, 2020 | -403.5% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2023 | Dec 31, 2023 | -440356600.0% | −440349780.4 |
| Q3 FY2023 | Sep 30, 2023 | -5993.4% | +55906.2 |
| Q2 FY2023 | Jun 30, 2023 | -5328.1% | +65489.1 |
| Q1 FY2023 | Mar 31, 2023 | -7307.6% | +2773.8 |
| Q4 FY2022 | Dec 31, 2022 | -6819.6% | −6626.8 |
| Q3 FY2022 | Sep 30, 2022 | -61899.6% | −61713.0 |
| Q2 FY2022 | Jun 30, 2022 | -70817.1% | −70112.5 |
| Q1 FY2022 | Mar 31, 2022 | -10081.5% | −8320.0 |
| Q2 FY2021 | Jun 30, 2021 | -192.8% | −4.3 |
| Q1 FY2021 | Mar 31, 2021 | -186.6% | +12.9 |
| Q4 FY2020 | Dec 31, 2020 | -704.7% | – |
| Q3 FY2020 | Sep 30, 2020 | -1761.4% | – |
| Q2 FY2020 | Jun 30, 2020 | -188.5% | – |
| Q1 FY2020 | Mar 31, 2020 | -199.4% | – |
See a number that looks wrong?